Find Academic Supervisors

Patrik ErnforsView profile

Professor

• Pain Research
• Neuroscience
• Molecular Biology
• +3 more

Patrik Ernfors is a Professor of Tissue Biology at the Karolinska Institutet (KI), affiliated with the Department of Medical Biochemistry and Biophysics. He is a leading researcher in pain biology and glioblastoma, with a focus on the cellular and molecular mechanisms underlying somatic sensation and chronic pain. Member of the Nobel Assembly (2007–present) Scientific Advisory Board, Knut and Alice Wallenberg Foundation (2022–present) His research employs single-cell RNA sequencing, mouse genetics, and neurophysiological methods to classify sensory neuron types, identify pain transduction mechanisms, and explore glioblastoma origins. He discovered a novel pain-sensing organ in the skin comprising glial cells and nerve fibers, and revealed that glioblastomas arise from blood vessel cells, not glial cells. Recent publications highlight his work on pain coding, Schwann cell roles in neuropathic pain, and molecular mechanisms in neuroblastoma. He has secured major grants from the Swedish Research Council, Deutsche Forschungsgemeinschaft, and Knut and Alice Wallenberg Foundation. Scientific awards include three ERC Advanced Grants and advisory roles in prestigious foundations. His lab at KI includes a team of researchers working on sensory neuron diversity, pain pathways, and glioma biology.

• Molecular Biology
• Genetics
• Cancer Research
• +6 more

Prof. Uğur GEZER is a Professor and Head of Department at Istanbul University's Oncology Institute, Department of Oncology. He has been with the institution since 2000, progressing from Instructor to Associate Professor and finally to Professor in 2012. His research focuses on molecular oncology with emphasis on cancer biomarker discovery using circulating tumor DNA, epigenetic modifications, and non-coding RNAs. Prof. GEZER received his undergraduate degree from Hacettepe University in Turkey (1988-1992), followed by postgraduate studies at Universitaet Kaiserslautern in Germany (1993-1996), and completed his doctorate at Ruprecht-Karls-Universitaet Heidelberg, Germany (1996-2000). His primary research interests include: Molecular mechanisms of cancer development and progression Circulating tumor DNA and liquid biopsy approaches Epigenetic modifications in cancer, particularly histone methylation Long non-coding RNAs in prostate and breast cancer Biomarker discovery for early detection and treatment monitoring Cancer genomics and repetitive elements in cell-free DNA Analysis of Prof. GEZER's recent publications reveals a strong focus on developing novel cancer biomarkers based on circulating nucleic acids. His work particularly emphasizes satellite DNA repeats, histone modifications, and long non-coding RNAs as potential diagnostic and prognostic tools. A significant portion of his research investigates prostate cancer mechanisms and biomarkers, with growing interest in breast cancer and colorectal cancer applications. Prof. GEZER has supervised numerous graduate students through their thesis work, with a focus on cancer molecular biology topics. His research has been supported by multiple projects from Higher Education Institutions, focusing on prostate cancer, breast cancer, and circulating biomarkers. His laboratory specializes in molecular techniques for analyzing circulating nucleic acids, histone modifications, and non-coding RNA expression, with applications in prostate cancer, breast cancer, and colorectal cancer research.

• Pediatric Oncology
• Pediatric Hematology
• Oncology
• +7 more

Rejin Kebudi is a Professor in Pediatrics and Pediatric Hematology-Oncology at Istanbul University's Cerrahpasa Medical Faculty and Oncology Institute. With over 40 years of clinical and academic experience, she specializes in pediatric oncology, retinoblastoma, medulloblastoma, and supportive care in oncology. Her leadership roles include chairing the SIOP Supportive Care Working Group and heading the Department of Preventive Oncology at Istanbul University. 1976-1982: Ege University Medical School 1985-1990: Pediatrics Residency & Pediatric Oncology Fellowship at Istanbul University 1992: Postdoctorate training at New York University, University of California Los Angeles, and Memorial Sloan Kettering Cancer Center Her research focuses on pediatric cancers, retinoblastoma genetics, supportive care in pediatric oncology, and global health initiatives. Recent publications address tumor biology, treatment outcomes, and psychosocial aspects of childhood cancer care. Key awards include the ASCO 2018 International Woman Who Conquer Cancer Mentorship Award and multiple best poster prizes at SIOP conferences. She has supervised 2 medical theses and serves on international oncology societies (SIOP, ASCO, ESMO, COG).

Micah DrummondView profile

Professor

• Aging
• Skeletal Muscle Physiology
• Metabolism
• +7 more

Micah Drummond serves as Professor of Physical Therapy & Athletic Training and Adjunct Professor across Nutrition & Integrative Physiology, Microbiology & Immunology, and Endocrinology & Metabolism at the University of Utah's College of Health. His primary appointment anchors him in the Department of Physical Therapy and Athletic Training, where he directs translational research on aging and muscle physiology. B.S. from California Lutheran University Ph.D. from Brigham Young University Dr. Drummond's research centers on skeletal muscle decline during aging and physical inactivity, investigating cellular mechanisms of muscle growth and metabolic dysfunction. His work pioneers therapeutic interventions—including nutritional compounds, pharmacological agents like metformin, and exercise protocols—to combat sarcopenia, insulin resistance, and inflammation. Key focus areas include immunometabolism, mitochondrial function, lipid signaling (e.g., ceramides), and macrophage-mediated muscle recovery, bridging molecular discoveries with clinical applications for older adults. Recent publications reveal accelerating trends in macrophage immunometabolism as a regrowth target, mitochondrial respiration modulation during disuse, and novel therapeutics (e.g., N-acetylcarnosine, stem cell secretomes) for multi-organ aging. His work increasingly integrates lipid hydroperoxide pathways, cellular senescence, and precision timing of exercise interventions, demonstrating how sedentarism drives metabolic inflexibility and muscle atrophy through pyruvate metabolism suppression. Dr. Drummond leads the Drummond Laboratory, leveraging the Skeletal Muscle Exercise Research Facility (SMERF) for human mobility/strength assessments and collaborating with the Center for Clinical and Translational Sciences for clinical trials. His team employs mechanistic mouse models, bed rest studies in older adults, and molecular techniques to parallel clinical muscle samples with whole-body functional metrics. He actively partners with the Diabetes and Obesity Metabolism Center and Health Sciences investigators to translate findings into therapies for age-related physical decline.

Kimberley EvasonView profile

Associate Professor

• Liver Cancer
• Hepatocellular Carcinoma (HCC)
• Wnt/β-catenin Signaling
• +3 more

Kimberley Evason serves as Associate Professor of Anatomic Pathology in the Department of Pathology at the University of Utah School of Medicine and Adjunct Assistant Professor of Oncological Sciences. Her research program at the Huntsman Cancer Institute focuses on liver cancer mechanisms and therapeutic development, leveraging zebrafish models to address critical challenges in hepatocellular carcinoma treatment. Education: B.S. from University of Iowa M.D. and Ph.D. from Washington University School of Medicine Dr. Evason's laboratory investigates β-catenin-activated hepatocellular carcinoma (HCC), which accounts for 20-40% of human cases. Her team developed transgenic zebrafish models expressing hepatocyte-specific activated β-catenin that develop HCC, enabling chemical screening for targeted therapies. Key discoveries include JNK inhibitors and serotonergic antidepressants (notably amitriptyline) that suppress tumor growth, with amitriptyline showing efficacy in mouse models. Current research explores molecular mechanisms of drug action and identifies conserved genetic pathways through RNA-seq analysis and functional validation in zebrafish and human cell lines. Analysis of her 2015-2019 publications reveals a cohesive research trajectory centered on liver cancer biology using zebrafish models. Her work integrates chemical screening, genetic analysis, and translational validation across multiple systems (zebrafish, mouse, human cells), with strong emphasis on Wnt/β-catenin signaling pathways. Publications span molecular mechanisms, tumor microenvironment interactions, and diagnostic innovations, demonstrating consistent focus on bridging basic science discoveries to clinical applications in HCC treatment. Dr. Evason leads a multidisciplinary research team at the Huntsman Cancer Institute, utilizing core facilities for zebrafish husbandry and advanced imaging. Her collaborative network includes oncologists, geneticists, and pharmacologists across the University of Utah, facilitating translational research from bench to bedside. The laboratory's resources and institutional support enable high-throughput chemical screening and sophisticated molecular analyses central to her therapeutic discovery pipeline.

Lisa LesniewskiView profile

Associate Professor

• Aging
• Obesity
• Adipose Tissue Biology
• +8 more

Lisa Lesniewski, Ph.D. , is an Associate Professor of Internal Medicine at the University of Utah School of Medicine and an Adjunct Assistant Professor of Nutrition and Integrative Physiology. She directs an active research program investigating the vascular and metabolic consequences of aging and obesity, with emphasis on adipose tissue biology, arterial dysfunction, and atherosclerosis. Education B.S., Ohio State University Ph.D., Texas A&M University Research Interests Dr. Lesniewski’s laboratory explores how aging and obesity synergistically impair vascular and metabolic health. Central themes include: Adipose tissue as an endocrine organ driving systemic inflammation and metabolic dysfunction. Telomere dysfunction and cellular senescence in adipose and arterial tissues. mTOR signaling and the potential of rapamycin-based interventions to counter vascular aging. MicroRNA networks—especially miR-92a—in arterial growth, aging, and atherosclerosis. The small GTPase ARF6 as a mechanosensitive regulator of endothelial inflammation and atherogenesis. Research Output & Trends Across more than 40 peer-reviewed publications (2019-2024), her group has advanced a translational pipeline from molecular mechanism (DNA damage, telomere uncapping, senolytic therapy) to organismal phenotype (arterial stiffness, glucose intolerance, atheroma burden) in both mouse models and human cohorts. A consistent innovation is the integration of high-resolution imaging biosensors with in-vivo vascular phenotyping to dissect single-cell metabolic heterogeneity within aged and obese tissues. Scientific Awards & Honors No specific awards are listed in the provided materials. Funding & Collaborative Networks Dr. Lesniewski has sustained NIH funding for projects spanning vascular aging, adipose inflammation, and metabolic dysfunction. She actively collaborates with investigators in Molecular Biology, Nutrition and Integrative Physiology, and Cardiovascular Medicine at the University of Utah, as well as with national geroscience consortia. Laboratory & Teams The Lesniewski Laboratory is housed within the University of Utah’s Molecular Medicine Program and has access to core facilities in metabolic phenotyping, advanced microscopy, and small-animal cardiovascular physiology. The team comprises post-doctoral fellows, graduate students, and research technicians working on parallel but integrated projects aimed at translating pre-clinical discoveries into therapeutic strategies for age-related cardiometabolic disease.

Anna ZolkiewskaView profile

Professor

• Triple negative breast cancer
• Tumor immune microenvironment
• ADAM metalloproteases
• +4 more

Dr. Anna Zolkiewska is a Professor in the Department of Biochemistry & Molecular Biophysics at Kansas State University where she serves as an Undergraduate Advisor. Her research program focuses on understanding the molecular mechanisms underlying triple-negative breast cancer (TNBC), with particular emphasis on tumor-initiating cells and the tumor microenvironment. She maintains active research collaborations through the Johnson Cancer Research Center and has been featured in their Conquest magazine publications in both 2012 and 2021. Education: M.S. (1984), University of Warsaw, Poland Ph.D. (1988), Nencki Institute of Experimental Biology, Warsaw, Poland Dr. Zolkiewska's research centers on the molecular mechanisms responsible for immunosuppression in triple-negative breast cancer. Her laboratory investigates how cell surface metalloproteases from the ADAM family, particularly ADAM12, contribute to the assembly of the immunosuppressive tumor microenvironment in TNBC. She employs multi-disciplinary approaches spanning biochemistry, molecular and cellular biology, and mouse models of human TNBC to discover mechanisms controlling immune cell infiltration into breast tumors. A significant portion of her work focuses on breast tumor-initiating cells (BTICs), which are resistant to conventional chemotherapy and radiotherapy and are believed to drive tumor recurrence and metastasis. Analysis of Dr. Zolkiewska's recent publications reveals a consistent focus on ADAM proteases, particularly ADAM12, and their role in breast cancer progression. Her work demonstrates how these metalloproteases influence cancer stem cell phenotypes, immune evasion mechanisms, and response to immunotherapies. A notable trend in her recent work is the exploration of ADAM12's role in modulating the tumor immune microenvironment and improving response to checkpoint blockade therapy, representing a shift toward more translational cancer immunology research. Scientific Recognition: Featured in Johnson Cancer Research Center's Conquest magazine (2012) Featured in Johnson Cancer Research Center's Conquest magazine (2021) As an active researcher and educator, Dr. Zolkiewska serves as an Undergraduate Advisor while maintaining a productive research program. Her laboratory has received research funding through various mechanisms including the Johnson Cancer Research Center's Innovative Research Awards and other cancer research funding opportunities at Kansas State University. Dr. Zolkiewska's work bridges basic molecular mechanisms with potential clinical applications, particularly in improving immunotherapy responses for triple-negative breast cancer patients. Her research team employs sophisticated biochemical, molecular, and cellular approaches to investigate cancer mechanisms, with recent work increasingly incorporating immunological perspectives and mouse models of human disease. This multi-faceted approach allows her laboratory to address complex questions about tumor biology from multiple angles.

Thuy Anh BuiView profile

Research Fellow

• Clinical Rehabilitation
• Musculoskeletal Diseases
• Health Service Research
• +4 more

Thuy Anh Bui is a Senior Research Fellow at the University of New South Wales, Faculty of Medicine, specializing in clinical rehabilitation and translational research. Originally from Vietnam, she completed her BSc and PhD in Physiology at the University of Manchester before transitioning from laboratory-based cardiovascular and cancer gene therapy research into clinical applications. Her current work bridges laboratory innovation with practical healthcare solutions, particularly for hip fracture patients in culturally diverse communities. Her research interests focus on clinical rehabilitation , musculoskeletal diseases , and health service research for culturally and linguistically diverse populations. She has published in high-impact journals including Nature Communications, Lancet eBiomedicine, and Advanced Functional Materials, demonstrating expertise that spans from basic science to clinical implementation. Her recent work shows a clear trajectory from cardiovascular and cancer gene therapy toward rehabilitation research, particularly in home-based care models. Bui leads the 'Rehabilitation in the Home' (RITH4Hips) randomized controlled trial, which received a $493,233 HCF Health Services Research Grant. This work builds on her previous success as project manager for the Hospital in the Home for Hip Fracture project at Liverpool Hospital, which was named a 2025 SWSLHD Quality Awards Finalist for Health Research. SWSLHD Quality Awards Finalists in Health Research, 2025 President's Doctoral Scholar Award, University of Manchester, UK, 2014-2018 Award for Excellence, Faculty of Life Sciences, University of Manchester, UK 2014 Outstanding Achievement Award, Faculty of Life Sciences, University of Manchester, UK, 2012 Silver Medal - 21st International Biology Olympiad 2010 First Prize - National Biology Olympiad, Vietnam 2010 As a supervisor, Bui is available to mentor ILP, Honours, Master, and PhD students in clinical trials for rehabilitation and musculoskeletal health, health service research for diverse populations, and translational research. Her community engagement work focuses on South West Sydney's culturally diverse communities, ensuring research addresses real-world healthcare disparities. She holds a Graduate Certificate in Higher Education Teaching and Learning from University of Technology Sydney, enhancing her capacity to develop future researchers.

• Pulmonary Fibrosis
• Influenza Virus Research
• MicroRNA Biology
• +5 more

Chaoqun Huang serves as a Research Assistant Professor in the Department of Physiological Sciences at Oklahoma State University, where they have been employed since 2018. Their research primarily focuses on molecular mechanisms underlying pulmonary diseases and viral infections, with particular emphasis on non-coding RNA regulation. Huang's research interests span several interconnected areas including pulmonary fibrosis pathogenesis, influenza virus and SARS-CoV-2 infection mechanisms, and the regulatory roles of microRNAs and long non-coding RNAs. Their work has significantly contributed to understanding how non-coding RNAs modulate viral replication and lung fibrosis processes. Notable research includes investigations into FENDRR, miR-9-1, miR-206, and other regulatory RNAs in the context of respiratory diseases. Analysis of their recent publications reveals a strong focus on identifying novel antiviral and anti-fibrotic mechanisms involving non-coding RNAs. Their work demonstrates how these molecules can serve as potential therapeutic targets for conditions like idiopathic pulmonary fibrosis and influenza virus infection. Huang frequently employs molecular biology techniques, animal models, and advanced sequencing approaches to uncover fundamental mechanisms of disease pathogenesis. Huang has received recognition for their contributions to understanding the molecular basis of pulmonary diseases and viral infections, as evidenced by citations across multiple publications. Their research has implications for developing novel therapeutic strategies targeting non-coding RNA pathways in respiratory diseases. Through collaborative research efforts, Huang has established expertise in both pulmonary fibrosis and viral pathogenesis, creating a unique interdisciplinary approach that bridges these two important areas of respiratory medicine. Their work continues to explore the complex interplay between host factors and disease mechanisms in the lung.

• Molecular Genetics
• Epigenetics
• Paediatric Neuro-oncology
• +4 more

Tania Corbett-Jones serves as a Research Fellow at the Centre for Genomics and Child Health within the Blizard Institute, Faculty of Medicine and Dentistry at Queen Mary University of London. She has been affiliated with Queen Mary since 2006, conducting collaborative research in bioinformatic pathway analysis, network modeling of experimental data, and karyotypic studies of human cell lines and primary tumors. Her research specializes in molecular mechanisms driving pediatric low-grade gliomas (pLGG), with particular focus on comparing pilocytic astrocytomas harboring KIAA1549-BRAF fusions versus glioneuronal tumors with BRAF V600E mutations. Both aberrations activate MAPK signaling but produce distinct phenotypes. She employs integrated multi-omics approaches combining RNA sequencing, LncRNA arrays, and phospho-proteomic analysis with Kinase-Substrate Enrichment Analysis (KSEA) to dissect downstream signaling mechanisms. This work aims to identify critical molecular effectors and validate findings using isogenic models developed in her laboratory. Publication trends reveal consistent progression from genetic characterization (2009-2011) toward sophisticated multi-omics integration (2015-2020), with increasing emphasis on epigenetic regulation and pathway crosstalk in pLGG. Her work spans molecular oncology, neurogenetics, and computational biology, primarily published in specialized journals like Acta Neuropathologica Communications and EMBO Reports. Within the Centre for Genomics and Child Health, Dr. Corbett-Jones collaborates across research groups utilizing core genomic and proteomic facilities. Her laboratory actively develops isogenic models to functionally validate molecular findings in pediatric glioma pathogenesis, contributing to translational research pipelines targeting MAPK pathway dysregulation.

• Medical Oncology
• Pathology
• Cancer Prognostic Biomarkers
• +4 more

Thomas Karsten Kilvær is an Associate Professor at the Department of Clinical Medicine , UiT The Arctic University of Norway. He is a member of the Translational Cancer Research Group (TCRG) and contributes to the AI–Pathology project. Research Focus : Prognostic biomarkers in cancer pathology, tumor microenvironment dynamics, and machine learning applications in histological analysis. Key Collaborations : Regular co-authorship with researchers like Mehrdad Rakaee, Sigve Andersen, and Roy M. Bremnes. Scientific Publications (selected) highlight trends in NSCLC , colon cancer , and soft tissue sarcomas , emphasizing immune cell infiltration, microRNA expression, and computational pathology. Current Projects include digital outpatient services for health literacy and AI integration in cancer diagnostics.

Gwenn A. GardenView profile

Professor

• Alzheimer's Disease
• Neuroinflammation
• Neurodegeneration
• +7 more

Gwenn A. Garden, MD, PhD is a Professor of Neurology and Chair of the Department of Neurology at the UNC School of Medicine . She also serves as Co-Director of the Duke/UNC Alzheimer's Disease Research Center , focusing on translational research in neurodegenerative diseases. Alzheimer's disease pathogenesis Neuroinflammation regulation Molecular cascades in neuronal degeneration Human tissue/stem cell research integration Her research bridges basic science with clinical applications, emphasizing neuroimmunology and microglial biology . Recent publications highlight her work on: 2023: Microglial transcriptomic changes in AD 2020: Cytokine roles in CAR T-cell neurotoxicity 2016: MicroRNA regulation of CNS inflammation Certifications and training: American Board of Psychiatry and Neurology (2012) MD and PhD in Physiology/Biophysics (University of Washington) Residency in Neurology (Harvard Longwood Program)

David HumphreysView profile

Researcher

• Bioinformatics
• Transcriptomics
• MicroRNAs
• +6 more

David Humphreys is a Senior Scientist and bioinformatician at the Victor Chang Cardiac Research Institute, affiliated with the University of New South Wales. He manages the Genomics and Bioinformatics Core Facility, specializing in high-throughput sequencing data generation and analysis. Dr. Humphreys holds a Bachelor of Science (Honours, 1994) and Doctor of Philosophy in Biological Sciences (1999). His primary research focuses on bioinformatics, transcriptomics, microRNAs, and congenital heart disease, with expertise spanning genomics, gene expression analysis, and epigenetics. He maintains active collaborations with faculty at the Victor Chang Institute and cardiologists at St Vincent's Hospital, employing RNA-Seq and exome/genome sequencing techniques. Dr. Humphreys has received notable scientific awards including the 2019 ABACBS Professional Bioinformatician award, 2015 NHMRC reviewer recognition, and multiple best presentation awards. His recent publications demonstrate a strong focus on cardiac development, genetic disorders, computational biology, and novel methodologies in genomics. As manager of the Genomics Core Facility, he oversees laboratory operations for sequencing library preparation and provides bioinformatics support for diverse research projects. His work bridges molecular biology and computational analysis to advance understanding of cardiovascular diseases and developmental disorders.

Satyanarayana R. PondugulaView profile

Professor

• Drug Discovery
• Drug Metabolism
• Drug Interactions
• +7 more

Dr. Satyanarayana R. Pondugula is a Professor of Veterinary Anatomy in the Department of Anatomy, Physiology and Pharmacology at Auburn University's College of Veterinary Medicine. He joined Auburn University in August 2011 after completing his DVM from the College of Veterinary Science in Tirupati, India, and his PhD from Kansas State University in Manhattan, Kansas, followed by postdoctoral training at St. Jude Children's Research Hospital in Memphis, Tennessee. Dr. Pondugula's research focuses on adverse drug interactions, anticancer drug resistance, and anticancer drug discovery. His laboratory investigates the mechanistic role of xenobiotic receptors, drug-metabolizing enzymes, drug-efflux pumps, and inflammatory signaling pathways that contribute to adverse drug interactions and anticancer drug resistance. His team also works on identifying novel small molecules and natural products for their potential to prevent adverse drug interactions, anticancer drug resistance, and adverse effects of chemotherapy. Analysis of Dr. Pondugula's recent publications reveals a strong emphasis on drug metabolism, particularly the pregnane X receptor (PXR) pathway, and its role in drug interactions and cancer treatment. His work spans multiple areas including veterinary oncology, chemotherapy-induced side effects, natural product pharmacology, and the neurological effects of drug interactions. Recent publications focus on cannabinoid interactions with cancer therapies, cardioprotective effects of natural products against chemotherapy-induced toxicity, and the impact of environmental chemicals on hormonal systems. Dr. Pondugula actively participates in teaching Veterinary Anatomy II to veterinary medicine and graduate students, as well as Endocrinology, Receptorology, Cancer Biology & Genetics, Cancer Pharmacology & Drug Discovery, and Pharmacology Research Methods courses. He also offers research-based Undergraduate Research, Honors Research, and Honors Thesis courses to undergraduate students. His collaborative research spans multiple institutions and involves numerous undergraduate and graduate students, as evidenced by publications in the Auburn University Journal of Undergraduate Scholarship. His work has significant implications for understanding drug interactions, improving cancer therapies, and developing safer treatment protocols for both human and veterinary medicine.

• Breast Cancer
• Endocrine Signaling
• Hormone-Dependent Cancers
• +5 more

Cathrin Brisken is an Associate Professor in Life Sciences at EPFL, with a secondary appointment at the Institute of Cancer Research London. She leads the Brisken Lab (https://brisken-lab.epfl.ch), focusing on breast cancer mechanisms, endocrine signaling, and precision medicine. Her roles include serving as Dean of the EPFL Doctoral School and co-founding the International Cancer Prevention Institute. Education: MD and PhD in Biophysics from the University of Göttingen, followed by postdoctoral training at MIT/Whitehead Institute and Harvard Medical School. Research interests center on hormonal regulation of mammary development and cancer, with breakthroughs in understanding sensor cell roles of estrogen/progesterone receptors. Her lab pioneered clinically relevant patient-derived xenograft models and investigates tumor dormancy, endocrine disruptors, and therapeutic targets in lobular carcinoma. Advising: Supervised over 15 PhD students (listed in detail in full description). Active in international committees like AACR Women in Cancer Research Council. Labs/Teams: Brisken Lab at EPFL develops innovative 3D ex vivo models and uses cutting-edge techniques like deep learning for spatial tissue analysis. Collaborates on programs like UPTIDER post-mortem tissue donation for metastatic research.